In 2025, rx/reimbursement adult incontinence in Poland showed stable volume growth, with sales reaching 270 million units, marking a 3% increase compared to the previous year. This steady expansion occurred in a context shaped predominantly by the reimbursement framework, which restricts patient choice and concentrates demand on standard absorbent products that fit within public reimbursement limits. While the broader region of Eastern Europe continues to see medical needs for adult incontinence

In 2025, Rx/reimbursement adult incontinence in Estonia continued to post robust volume growth, with sales rising 3% year-on-year to reach 8.7 million units. This marked a notable acceleration compared to the previous year's 1% growth, and stands out in the context of Eastern Europe, where volume expansion in similar categories is generally more subdued due to demographic plateauing and cost containment efforts. The growth in Estonia was driven by the interplay of population ageing, healthcare f

Rx/reimbursement adult incontinence in Turkey saw volume sales grow by 4% in 2025, only slightly slower than in 2024, to reach 311 million units. The category performance is anchored in two structural drivers: the demographic momentum of an ageing population and the continued stability of government reimbursement policy. The 65-year-old-and-over population rose to 9.1 million in 2025. This cohort's continued expansion underpins the demand for moderate/heavy adult incontinence products, especiall

In 2025, Rx/reimbursement adult incontinence in Argentina remained a government-prioritised essential, with annual distribution volumes reaching 196 million units, reflecting growth of 1% over the previous year. Unlike many other fast-moving consumer goods, volume growth in this area is largely decoupled from economic cycles or government budget fluctuations, as the product is regarded as a necessity for the elderly population and is supported through the national health system. While other Lati

In 2025, rx/reimbursement adult incontinence in Lithuania continues to post strong volume growth, reaching 38 million units, up 3% from the previous year. This growth is set against a backdrop of an ageing population, with those aged 65 and above increasing to 603,500 individuals in 2025, supporting ongoing demand expansion. Consumer expenditure also rose in 2025, hitting EUR45.9 billion, indicating improved purchasing power and willingness to invest in health-related products. The value sales m

In 2025, rx/reimbursement adult incontinence in Hungary demonstrated continued volume and value growth, reaching 182 million units, representing a 2% increase from the previous year, and 6% value growth increase to HUF17.1 billion. This performance reflects a positive trend, although the pace of growth moderated after a stronger 6% volume rise in 2024. Sales are closely linked to demographic shifts, with Hungary’s total population declining to 9.5 million, but with the population aged 65 and ove

In 2025, rx/reimbursement adult incontinence in Croatia continued to record steady volume growth, supported by both demographic factors and evolving patient behaviour. Volume reached 6.1 million units in 2025 representing an increase of 2%. This growth rate, while slightly slower than in previous years, remains positive and structurally driven by higher utilisation of medical aids, as confirmed by the Croatian health insurance institute’s (HZZO) financial plan for 2025–2027, which anticipates fu

Rx/reimbursement adult incontinence in Switzerland recorded 1% value growth to CHF40 million in 2025, driven by an ageing Swiss population requiring long-term care and consistent incontinence management. Units distributed through the reimbursement channel grew from 47.6 million in 2024 to 48.3 million in 2025, reflecting 1% growth in line with Switzerland’s demographic trend as the total population rose to 9 million and the population aged 65 and over increased from 1.7 million to 1.8 million. R

RX/reimbursement adult incontinence records 3% value growth to USD8 million in 2025, with volume reaching 15 million units, representing 2% growth versus the previous year. This reflects a stable and steadily expanding environment, notable within the broader Latin American context, where consistent access to reimbursed products remains less common.

In 2025, rx/reimbursement adult incontinence in Austria recorded stable yet subdued growth in both volume and value compared to previous years and in line with broader European trends. Sales reached 114 million units, representing a less than 1% increase from 2024, while manufacturer selling prices in local currency rose by 3% to EUR36 million. This muted expansion reflects a mature landscape where rising demand from an ageing population is balanced by affordability challenges and public budget

In 2025, rx/reimbursement adult incontinence in Colombia experienced positive growth, with volume reaching 196 million units, a year-on-year increase of 3% compared to the previous year. This growth follows a recovery from a steep decline in 2024 and is supported by a 9% increase in manufacturer selling price value to COP392 billion. The underlying driver of this performance is the ongoing reliance on the public health system, where EPS (Entidades Promotoras de Salud) dispenses these products th

In 2025, rx/reimbursement adult incontinence in Kazakhstan demonstrated robust volume and value growth, standing out in the regional and global context. Volume reached 195 million units, marking a 4% increase over the previous year, while value surged to KZT73.5 billion with a growth rate of 16%. This strong performance was driven by the expanding elderly population, with the total number of people aged 65 and over rising to 2 million, contributing to increased demand for moderate and heavy abso

In 2025, Rx/reimbursement adult incontinence in Slovakia recorded continued positive sales growth, with volume reaching 258.5 million units and a year-on-year increase of 1%. The category experienced strong current value growth of 5%, with sales rising to EUR81.6 million. This robust growth trajectory was driven primarily by a combination of demographic and regulatory factors, while, globally, the category’s expansion aligns with trends in ageing populations and rising demand for medical incont

In 2025, total value sales for rx/reimbursment adult incontinence in the Netherlands increased by 1% in current terms to EUR149 million. In contrast, the category continued a pattern of volume decline, with volume sales falling from 410 million units in 2024 to 403 million units in 2025, representing a decrease of 2%. This downward trend has been present for several years, driven by both demographic and behavioural factors.

In 2025, rx/reimbursement adult incontinence in Spain continued to expand in both volume and value, although growth decelerated compared to the preceding years. Volume reached 461 million units, up 2% from 2024, marking a notable slowdown from the 5% increase recorded the year before. Value growth mirrored this trend, with total sales rising to EUR295 million, representing a 2% increase year-on-year, down from 5% growth in 2024. This moderation reflects the impact of regulatory tightening and a

In 2025, rx/reimbursement adult incontinence in Serbia demonstrated resilient volume growth, reaching 5.5 million units, reflecting a 2% increase from the previous year. This continued, albeit slower, expansion is underpinned by Serbia’s state reimbursement programme, which regularly reviews and increases the maximum reimbursement amount for incontinence products, thereby providing stability and predictability for both patients and suppliers. This policy environment supports ongoing demand, even

In 2025, Rx/reimbursement adult incontinence in Latvia demonstrated solid performance, with volume reaching 25.6 million units and a value of EUR9.1 million. Growth accelerated in 2025, with volume increasing by 3% and value up by 5%, after a period of stagnation in 2024. Market growth outpaced the overall consumer expenditure trend, highlighting that demand for these products is resilient even in a challenging economic context.

Rx/reimbursement adult incontinence in Norway demonstrated steady volume growth in 2025, reaching 13 million units, with an annual growth rate of 2%. In value terms, the category reached NOK33 million in 2025, rising by 4% compared to the previous year, which signals not only robust demand but also successful premiumisation and value capture, despite broader regional and global economic pressures. This performance reflects a continuation of the upward trajectory observed over previous years and

In 2025, Rx/reimbursement adult incontinence in Denmark continued its trajectory of steady expansion, reaching sales of 111 million units, up 1% from 2024. This growth rate, while lower than the 2% growth seen in the previous year, still outpaced much of the broader Western European context, where category maturity and population dynamics often lead to more modest gains. The consistent increase is directly tied to the rising share of older adults in Denmark, with total population reaching 6.0 mi

In 2025, rx/reimbursement adult incontinence in Israel demonstrated a steady performance, with growth shaped almost exclusively by structural and macroeconomic pressures rather than by innovation or expansion in product offerings. Volume reached 36 million units, up 3% from the previous year, while value rose to ILS97 million, reflecting a 7% increase. This performance was underpinned by a focus on affordability, as reimbursement budgets and tender frameworks maintained a strict emphasis on cost

In 2025, rx/reimbursement adult incontinence in Italy experienced another year of decline, with volume reaching 162 million units, down from 171 million units in 2024, a decrease of 6%. The value of the category also declined to EUR79 million in 2025, compared to EUR80 million in 2024, reflecting a drop of 2%. This contraction is consistent with a multi-year trend of declining expenditure in the Italian national sanitary system’s reimbursement scheme, where both product and service quality have

Rx/reimbursement adult incontinence in France maintained a positive trajectory in 2025, with volume sales reaching 49 million units and current value at EUR29 million. The year saw continued growth in volume, reflecting the essential nature of these products and the resilience of demand. While regional Western Europe markets also experience growth in this area, France’s performance aligns closely with demographic shifts, as its total population reached 66 million in 2025, with the population age

Rx/reimbursement adult incontinence in Brazil delivered a notable performance in 2025, with volumes reaching 122 million units, representing a year-on-year increase of 6%. This outpaced the previous year’s 2% growth and was stronger than the average trend observed in Latin America, reflecting the direct impact of domestic public health policies. The underlying demographic trend also boosted demand, with the population aged 65+ reaching 24.3 million in 2025, up by a million from the previous year

Rx/reimbursement adult incontinence in the United Kingdom continued to face a challenging environment in 2025, with volume sales declining by 1% to fall to 505 million units. This negative demand trend is part of a longer pattern. Despite broader demand for incontinence management products being driven by an ageing population and rising obesity rates, specific structural issues, particularly long waiting times within the NHS, have constrained growth in Rx/reimbursement adult incontinence. Consum